
Turkish Entrepreneur's Company Market Value to an Impressive $5.8 Billion
BillionToOne, a biotech firm established by Turkish entrepreneur Oğuzhan Atay in 2016, made its public debut on Nasdaq just the other day. Founded with the aim of developing genetic tests conducted via blood samples for common diseases such as sickle cell anemia and cystic fibrosis, the company has been a source of joy for its investors from day one. By the close of its first day of trading, the share price of the company, which started at $60, soared to $109, pushing the company's market value up to a staggering $5.8 billion.



















